Ethiopian Airlines Awards Design Consultancy Contract for Ethiopia’s New Global Hub Airport to a Consortium Led by Dar and Zaha Hadid Architects
Ethiopian Airlines Group has announced plans to build Africa’s largest airport in Abusera – a critical element of Ethiopian’s 15-year strategic plan to become one of the most competitive aviation groups in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240812311709/en/
Ethiopian Airlines Group CEO Mesfin Tasew and Dar’s Director of Operations in Ethiopia Tariq Al-Qanni sign consultancy contract for new Abusera International Airport. (Photo: AETOSWire)
The airport’s location allows for progressive growth, empowering the airline to meet the International Air Transport Association’s forecasts of more than 200% growth over the next decade – growing beyond Bole International Airport, which offers no possibilities for significant expansion. Abusera’s lower altitude will elevate aircraft take-off performance, while an express rail link to Addis Ababa facilitates connectivity.
In its first phase scheduled for 2029, the airport will have capacity for 60 million passengers annually – almost three times Africa’s current busiest airport – creating thousands of jobs to serve Ethiopian’s expanding customer base and fleet. Ultimately, the airport will serve 110 million passengers annually – four times the capacity of Bole International Airport.
Ethiopian’s CEO Mesfin Tasew stated: “With its exceptional capacity and world-class facilities, this new airport promises to elevate African aviation.”
To deliver this transformational new project, Ethiopian Airlines awarded a consultancy contract to a consortium led by Dar Al-Handasah Consultants (Shair and Partners), with Zaha Hadid Architects (ZHA),Pascall+Watson Architects, Landrum&Brown, and TY Lin.
Dar, TY Lin, and Landrum&Brown belong to Sidara, a global collaborative that ranks 1st in aviation (Engineering News Record 2023). ZHA brings award-winning design capabilities and a global track-record of acclaimed airport projects, while Pascall+Watson Architects has successfully completed over 2,000 aviation projects across 70 airports.
Collectively, these companies will cover technical advisory, engineering, project management, and construction supervision services for 600,000 m2 of passenger facilities, 126,000 m2 of airline support facilities, two Code 4E parallel runways along with associated airfield infrastructure, and other major airport facilities and infrastructure.
About Ethiopian Airlines Group
Ethiopian is one of the fastest-growing airlines globally and the largest in Africa. Building on a highly successful 78-year track record, Ethiopian operates Africa’s most modern fleet to more than 150 destinations across five continents.
https://www.ethiopianairlines.com/et
About Dar
Dar provides design, planning, engineering, and management services for buildings, cities, transportation, and infrastructure projects.
About Zaha Hadid Architects (ZHA)
Founded 45 years ago in London, ZHA offers architecture, design, and planning services worldwide.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812311709/en/
Contacts
Dar – Marketing & Communications
Haya Yahya
MC@dar.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press Release
On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom